Epoxyeicosatrienoic acid: A potential therapeutic target of heart failure with preserved ejection fraction - 31/08/22
Abstract |
Heart failure with preserved ejection fraction (HFpEF) reduces the quality of life, costs substantial medical resources, and has a high mortality. However, we lack an effective therapy for HFpEF due to our limited knowledge of its mechanism. Therefore, it is crucial to explore novel therapeutics, such as those with endogenous protective roles, and seek new targeted therapies. Epoxyeicosatrienoic acids (EETs) are endogenous bioactive metabolites of arachidonic acids produced by cytochrome P450 (CYP) epoxygenases. EETs can function as endogenous cardioprotective factors with potent inhibitory roles in inflammation, endothelial dysfunction, cardiac remodeling, and fibrosis, which are the fundamental mechanisms of HFpEF. This suggests that EETs have the potential function to protect against HFpEF. Therefore, we present an overview of the ever-expanding world of EETs and how they might help alleviate the pathophysiology underlying HFpEF to provide new insights for research in this field.
Le texte complet de cet article est disponible en PDF.Graphical Abstract |
Highlights |
• | Epoxyeicosatrienoic acids (EETs) function as endogenous cardioprotective factors with potent inhibitory roles in inflammation, endothelial dysfunction, cardiac remodeling, and fibrosis, which are the fundamental mechanisms of HFpEF. |
• | EETs may be a potential therapeutic target of HFpEF. |
Keywords : Epoxyeicosatrienoic acid, Heart failure with preserved ejection fraction, Inflammation, Endothelial dysfunction, Cardiomyocyte remodeling, Fibrosis
Abbreviations : EETs, HFpEF, CYP, AA, sEH
Plan
Vol 153
Article 113326- septembre 2022 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?